Saturday, September 23, 2023
Saturday, September 23, 2023

Compression Works Receives Additional 510(k) Clearance from the FDA for the AAJT-S Life-Saving Junctional Tourniquet

Compression Works, Inc. manufacturer of the Abdominal Aortic and Junctional Tourniquet-Stabilized (AAJT-S) device, announces a new 510(k) clearance from the FDA.  This is the third 510(k) clearance granted by the U.S. Food and Drug Administration (FDA) for the AAJT-S technology.

The AAJT-S junctional tourniquet is designed to control non-compressible hemorrhages in the junctional areas of the anatomy, on the abdomen and for pelvic fracture stabilization. “We are thrilled at the ever-expanding indication range for the AAJT-S and are happy to announce this new clearance by the FDA,” said President and CEO of Compression Works Scott Dodson. “Pelvic fractures that result from automobile accidents, crushing injuries and falls represent a serious health issue and even mortality for accident victims due to their potential to rupture the underlying blood vessels in this area,” said Dodson.

“The U.S. Department of Transportation reports 150,000 pelvic fractures per year. Of those that die, up to 40% are as a result of an underlying hemorrhage due to the disruption in the pelvis. The AAJT-S device can stabilize the broken structure so the accident victim can be safely transported to definitive care for an awaiting surgical team.  If there is suspected pelvic bleeding, the AAJT-S can also be used to stop the blood flow to the damaged area,” stated Chief Medical Officer John Croushorn, MD.

The AAJT-S from Compression Works has five distinct uses. The device can be used in the axilla and groin to stop junctional hemorrhage, and is the only junctional tourniquet cleared for use on the abdomen for pelvic bleeding and bilateral lower leg injuries. The AAJT-S can also be used as an adjunct to Zone 3 REBOA as proven in multiple peer-reviewed clinical studies.  With the additional FDA clearance for pelvic fractures, the AAJT-S offers more multi-use capabilities for critical areas of the body to help save lives.

Medical Device News Magazine
Our publication is dedicated to bringing our readers the latest medical device news. We are proud to boast that our subscribers include medical specialists, device industry executives, investors, and other allied health professionals, as well as patients who are interested in researching various medical devices. We hope you find value in our easy-to-read publication and its overall purpose and objectives! Medical Device News Magazine is a division of PTM Healthcare Marketing, Inc. Pauline T. Mayer is the managing editor.


FDA Grants Fast Track Designation to 9MW3011

9MW3011 has been approved to clinical study by NMPA and FDA, respectively. The first person has been dosed in the clinical study in China in March, 2023.

MicuRx receives FDA Qualified Infectious Disease Product (QIDP) and Fast Track Designation for Contezolid and Contezolid acefosamil

"We are pleased to gain the QIDP and Fast Track designations for DFI as recognition that contezolid and contezolid acefosamil are novel new agents to meet an important unmet need in this common and challenging infection", stated Dr Zhengyu Yuan, Chief Executive Officer at MicuRx. 

Via Nova Therapeutics Announces FDA clearance of Investigational New Drug (IND) Application for VNT-101

"We look forward to evaluating VNT-101 in the clinic," said Don Ganem MD, Co-Founder and CEO of Via Nova Therapeutics. "This is an important step to developing a flu antiviral with a novel mechanism of action, and a milestone for Via Nova Therapeutics as we advance our first compound into the clinic."

FDA OK’s ensoETM for Use in Cardiac Ablations to Reduce Risk of Esophageal Injury

Published studies that have examined the use of ensoETM for this purpose include the pilot eCOOL-AF study, the IMPACT study and a large multi-center analysis of over 25,000 patients (in press at the Journal of the American College of Cardiology: Clinical Electrophysiology). These studies have found up to an 83 percent reduction in esophageal injuries, and a significant reduction in risk of atrioesophageal fistula (AEF), one of the most dreaded complications of ablation procedures. Receives FDA Clearance and Breakthrough Device Designation has also received FDA Breakthrough Device Designation for its obstructive hydrocephalus software tool. This is the first radiology triage device to be granted Breakthrough status since the inception of the FDA Breakthrough Devices Program.

By using this website you agree to accept Medical Device News Magazine Privacy Policy